Cancer vaccines targeting Her2 together with the application of strategies to deplete Tregs and MDSCs might thus provide clinical benefit even in older breast cancer patients whose immune systems are generally considered to be compromised by the ageing process. This evidence concerns the gene ERBB2 and breast cancer.